No Access

Chinese Herbal Medicine for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Division of Respiratory Medicine, Department of Integrated Traditional and Western Medicine, West China Hospital of Sichuan University, 37 Guoxue Lane, Chengdu, Sichuan 610041, P. R. China

Search for more papers by this author

Wei Liu

Division of Respiratory Medicine, Department of Integrated Traditional and Western Medicine, West China Hospital of Sichuan University, 37 Guoxue Lane, Chengdu, Sichuan 610041, P. R. China

Search for more papers by this author

Hong-Li Jiang

Division of Respiratory Medicine, Department of Integrated Traditional and Western Medicine, West China Hospital of Sichuan University, 37 Guoxue Lane, Chengdu, Sichuan 610041, P. R. China

E-mail Address: doc_jhl@163.com

Correspondence to: Dr. Hong-Li Jiang, Division of Respiratory Medicine, Department of Integrated Traditional and Western Medicine, West China Hospital of Sichuan University, 37 Guoxue Lane, Chengdu, Sichuan 610041, P. R. China. Tel: (+86) 18980606651.

Search for more papers by this author

, and

Bing Mao

Division of Respiratory Medicine, Department of Integrated Traditional and Western Medicine, West China Hospital of Sichuan University, 37 Guoxue Lane, Chengdu, Sichuan 610041, P. R. China

Search for more papers by this author

https://doi.org/10.1142/S0192415X18500490Cited by:65 (Source: Crossref)

Abstract

Chinese herbal medicine (CHM) has been widely used in the treatment of advanced non-small-cell lung cancer (NSCLC), but their efficacy and safety remain controversial. We sought to comprehensively aggregate and evaluate the available evidence on the efficacy and safety of the combination treatment with CHM and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC patients. Our exhausted and systematical searching strategy yielded 64 related randomized controlled trials involving 4384 patients. Compared with EGFR-TKIs therapy alone, meta-analysis showed significant differences favoring the combination treatment in progression-free survival ( $P < 0.0001$ $P < 0.0001$ ), median survival time ( $P < 0.0001$ $P < 0.0001$ ), one-year survival rate ( $P = 0.002$ $P = 0.002$ ), two-year survival rate ( $P = 0.005$ $P = 0.005$ ), probability of severe toxicities ( $P < 0.0001$ $P < 0.0001$ ), objective response rate ( $P < 0.0001$ $P < 0.0001$ ), Karnofsky performance status ( $P < 0.0001$ $P < 0.0001$ ), and improvement in percentage of CD3 $^{+}$ $^{+}$ T lymphocyte ( $P < 0.0001$ $P < 0.0001$ ) and CD4 $^{+}$ $^{+}$ T lymphocyte ( $P < 0.0001$ $P < 0.0001$ ). Though these results require further confirmation, they are prone to show a potential therapeutic value of CHM in improving the clinical effect, overcoming the drug resistance and toxicities as an adjunctive therapy to EGFR-TKIs.

Keywords:

Remember to check out the Most Cited Articles!
Check out our Chinese Medicine Titles today. Includes titles by Nobel Winner, Tu You You and more!

References

Abe, A., H. Yamada, S. Moriya and K. Miyazawa . The beta-carboline alkaloid harmol induces cell death via autophagy but not apoptosis in human non-small cell lung cancer A549 cells. Biol. Pharm. Bull. 34: 1264–1272, 2011. Crossref, Medline, Web of Science, Google Scholar
Cao, Y.J., D.L. Wang, C.W. Liu, F. Du, L.Y. Hao, F. Cao, W. Li and C. Zhao . To explore the effect of Gefitinib and Brucea javanica oil emulsion (BJOE) for advanced non-small cell lung cancer. Clin. J. Chin. Med. 146–148, 2014. Google Scholar
Costa, D.B., S. Kobayashi, D.G. Tenen and M.S. Huberman . Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58: 95–103, 2007. Crossref, Medline, Web of Science, Google Scholar
Costa, D.B., K.S. Nguyen, B.C. Cho, L.V. Sequist, D.M. Jackman, G.J. Riely, B.Y. Yeap, B. Halmos, J.H. Kim, P.A. Janne, M.S. Huberman, W. Pao, D.G. Tenen and S. Kobayashi . Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin. Cancer Res. 14: 7060–7067, 2008. Crossref, Medline, Web of Science, Google Scholar
Dai, P.C., D.L. Liu, L. Zhang, J. Ye, Q. Wang, H.W. Zhang, X.H. Lin and G.X. Lai . Astragaloside IV sensitizes non-small cell lung cancer cells to gefitinib potentially via regulation of SIRT6. Tumour Biol. 39: 1010428317697555, 2017. Crossref, Google Scholar
Delbaldo, C., S. Michiels, E. Rolland, N. Syz, J.C. Soria, T. Le Chevalier and J.P. Pignon . Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst. Rev. Cd004569, 2007. Medline, Web of Science, Google Scholar
Dong, L., D. Lei and H. Zhang . Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients. Oncotarget 8: 64600–64606, 2017. Crossref, Medline, Google Scholar
Duval, S. and R. Tweedie . Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56: 455–463, 2000. Crossref, Medline, Web of Science, Google Scholar
Fang, F., H. Chen, H.M. Pang, W.G. Song, R.L. Wang and H.B. Wang . Clinical observation of gefitinib combined with Zilongjin tablets in treatment of advanced non-small-cell lung cancer. Mod. Prev. Med. 38: 1346–1348, 2011a. Google Scholar
Fang, F., H. Chen, H. Zhao, T. Pan, H. Yang and S.M. Dai . Clinical observation of gefitinib combined with Pingxiao capsule in treatment of advanced NSCLC. Chin. J. Mod. Med. 21: 883–886, 2011b. Google Scholar
Fang, F., H. Chen, Y. Xiao, A.H. Duan, G.P. Du and C.F. Bu . Clinical evaluation of gefitinib combined with Zhenqi Fuzheng capsule in treatment of senile advanced non-small-cell lung cancer. Chin. J. Geriatr. 1: 33–35, 2012. Google Scholar
Fu, S., Y. Yang, D. Liu, Y. Luo, X. Ye, Y. Liu, X. Chen, S. Wang, H. Wu, Y. Wang, Q. Hu and P. You . Flavonoids and tannins from Smilax china L. rhizome induce apoptosis via mitochondrial pathway and MDM2-p53 signaling in human lung adenocarcinoma cells. Am. J. Chin. Med. 45: 369–384, 2017. Link, Web of Science, Google Scholar
Han, Y., H. Wang, W. Xu, B. Cao, L. Han, L. Jia, Y. Xu, Q. Zhang, X. Wang, G. Zhang, M. Yu and G. Yang . Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients. Complement. Ther. Med. 24: 81–89, 2016. Crossref, Medline, Web of Science, Google Scholar
Higgins, J.P., S.G. Thompson, J.J. Deeks and D.G. Altman . Measuring inconsistency in meta-analyses. BMJ 327: 557–560, 2003. Crossref, Medline, Web of Science, Google Scholar
Higgins, J.P.T. and S. Green (eds.). Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, USA, 2011. Google Scholar
Jia, Y.J. and X.Z. Wu . Oncology of Integrated Traditional Chinese and Western Medicine. Huazhong University of Science and Technology Press, Wuhan, 2009. Google Scholar
Kang, T.H., J.Y. Bang, M.H. Kim, I.C. Kang, H.M. Kim and H.J. Jeong . Atractylenolide III, a sesquiterpenoid, induces apoptosis in human lung carcinoma A549 cells via mitochondria-mediated death pathway. Food Chem. Toxicol. 49: 514–519, 2011. Crossref, Medline, Web of Science, Google Scholar
Li, F.R. Randomized controlled study of Fuzheng Kang’ai decoction combined with gefitinib in treatment of advanced NSCLC. Guangzhou University of Chinese Medicine, 2013. Google Scholar
Li, S., H. Chen, C. Ou-Yang, X. Wang, Z. Yang, Y. Tong and W. Cho . The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis. PLoS One 8: e57604, 2013a. Crossref, Medline, Web of Science, Google Scholar
Li, X., P. Xin, C. Wang, Z. Wang, Q. Wang and H. Kuang . Mechanisms of traditional Chinese medicine in the treatment of mammary gland hyperplasia. Am. J. Chin. Med. 45: 443–458, 2017. Link, Web of Science, Google Scholar
Li, X.T., J.J. Tan, R.P. Yu and T.Z. Jia . Traditional Chinese medicine in reversal of multi-drug resistance. J. Liaoning Univ. Trad. Chin. Med. 15: 155–158, 2013b. Google Scholar
Li, Z.Y., W.C. Huang, R.S. Tu, P.Y. Gu, C.F. Lin and C.J. Liou . Sophoraflavanone G induces apoptosis in human leukemia cells and blocks MAPK activation. Am. J. Chin. Med. 44: 165–176, 2016. Link, Web of Science, Google Scholar
Liang, H. , Clinical study on 30 cases of advanced lung adenocarcinoma treated with TCM treatment based on syndrome differentiation combined with gefitinib. Integr. J. Trad. Chin. Med. 34: 502–505, 2012. Google Scholar
Liu, Y., Y. Zhang, G. Feng, Q. Niu, S. Xu, Y. Yan, S. Li and M. Jing . Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non-small cell lung cancer: A network meta-analysis. Exp. Ther. Med. 14: 4017–4032, 2017. Medline, Web of Science, Google Scholar
Liu, Z.L., W.R. Zhu, W.C. Zhou, H.F. Ying, L. Zheng, Y.B. Guo, J.X. Chen and X.H. Shen . Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: A systematic review and meta-analysis. J. Integr. Med. 12: 346–358, 2014. Crossref, Medline, Google Scholar
McCulloch, M., C. See, X.J. Shu, M. Broffman, A. Kramer, W.Y. Fan, J. Gao, W. Lieb, K. Shieh and J.M. Colford, Jr. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: Meta-analysis of randomized trials. J. Clin. Oncol. 24: 419–430, 2006. Crossref, Medline, Web of Science, Google Scholar
Molina, J.R., P. Yang, S.D. Cassivi, S.E. Schild and A.A. Adjei . Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83: 584–594, 2008. Crossref, Medline, Web of Science, Google Scholar
Nguyen, K.S. and J.W. Neal . First-line treatment of EGFR-mutant non-small-cell lung cancer: The role of erlotinib and other tyrosine kinase inhibitors. Biologics 6: 337–345, 2012. Medline, Google Scholar
Orlikova, B., N. Legrand, J. Panning, M. Dicato and M. Diederich . Anti-inflammatory and anticancer drugs from nature. Cancer Treat. Res. 159: 123–143, 2014. Crossref, Medline, Google Scholar
Poornima, P., C.F. Weng and V.V. Padma . Neferine from Nelumbo nucifera induces autophagy through the inhibition of PI3K/Akt/mTOR pathway and ROS hyper generation in A549 cells. Food Chem. 141: 3598–3605, 2013. Crossref, Medline, Web of Science, Google Scholar
Qian, J., S.K. Qin, L.Q. Yang, Y.X. Chen and Z.J. Shao . The clinical study of Gefitnib combination with Kanglaite injection in treatment of non-small-cell lung cancer. China J. Chinese Mater. Med. 9: 568–570, 2004. Google Scholar
Robinson, A.G., C.M. Booth and E.A. Eisenhauer . Progression-free survival as an end-point in solid tumours-perspectives from clinical trials and clinical practice. Eur. J. Cancer 50: 2303–2308, 2014. Crossref, Medline, Web of Science, Google Scholar
Satoh, H., A. Inoue, K. Kobayashi, M. Maemondo, S. Oizumi, H. Isobe, A. Gemma, Y. Saijo, H. Yoshizawa, K. Hagiwara and T. Nukiwa . Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. J. Thorac. Oncol. 6: 1413–1417, 2011. Crossref, Medline, Web of Science, Google Scholar
Shepherd, F.A., J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, S. Thongprasert, D. Campos, S. Maoleekoonpiroj, M. Smylie, R. Martins, M. van Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabarbara and L. Seymour . Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353: 123–132, 2005. Crossref, Medline, Web of Science, Google Scholar
Siegel, R.L., K.D. Miller and A. Jemal . Cancer statistics, 2017. CA Cancer J. Clin. 67: 7–30, 2017. Crossref, Medline, Web of Science, Google Scholar
Simes, R.J. , Confronting publication bias: A cohort design for meta-analysis. Stat. Med. 6: 11–29, 1987. Crossref, Medline, Web of Science, Google Scholar
Sterne, J.A., A.J. Sutton, J.P. Ioannidis, N. Terrin, D.R. Jones, J. Lau, J. Carpenter, G. Rucker, R.M. Harbord, C.H. Schmid, J. Tetzlaff, J.J. Deeks, J. Peters, P. Macaskill, G. Schwarzer, S. Duval, D.G. Altman, D. Moher and J.P. Higgins . Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343: d4002, 2011. Crossref, Medline, Web of Science, Google Scholar
Sutton, A.J., K.R. Abrams, D.R. Jones, T.A. Sheldon and F. Song . Methods for Meta-Analysis in Medical Research. John Wiley & Sons, Chichester, United Kingdom, 2000. Google Scholar
Therasse, P., S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein, J. Verweij, M. Van Glabbeke, A.T. van Oosterom, M.C. Christian and S.G. Gwyther . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92: 205–216, 2000. Crossref, Medline, Web of Science, Google Scholar
Tong, C., W. Wu, H. Loong, W. Cho and K. To . Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. Cancer Lett. 405: 100–110, 2017. Crossref, Medline, Web of Science, Google Scholar
Torre, L.A., F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent and A. Jemal . Global cancer statistics, 2012. CA Cancer J. Clin. 65: 87–108, 2015. Crossref, Medline, Web of Science, Google Scholar
Uno, H., B. Claggett, L. Tian, E. Inoue, P. Gallo, T. Miyata, D. Schrag, M. Takeuchi, Y. Uyama, L. Zhao, H. Skali, S. Solomon, S. Jacobus, M. Hughes, M. Packer and L.J. Wei . Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J. Clin. Oncol. 32: 2380–2385, 2014. Crossref, Medline, Web of Science, Google Scholar
Wang, C.Z., S. Anderson and C.S. Yuan . Phytochemistry and anticancer potential of notoginseng. Am. J. Chin. Med. 44: 23–34, 2016a. Link, Web of Science, Google Scholar
Wang, Q., Q. Wang, S. Wang, L. Jiao, R. Zhang, Y. Zhong, J. Zhang and L. Xu . Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis. Curr. Oncol. 24: e269–e276, 2017. Crossref, Medline, Web of Science, Google Scholar
Wang, S., Q. Wang, L. Jiao, Y. Huang, D. Garfield, J. Zhang and L. Xu . Astragalus-containing Traditional Chinese Medicine, with and without prescription based on syndrome differentiation, combined with chemotherapy for advanced non-small-cell lung cancer: A systemic review and meta-analysis. Curr. Oncol. 23: e188–195, 2016b. Crossref, Medline, Web of Science, Google Scholar
Wang, W., H. Wang, C.M. Wang, S. Gou, Z.H. Chen and J. Guo . Treatment with Huisheng oral solution inhibits the development of pulmonary thromboembolism and metastasis in mice with Lewis lung carcinoma. Oncol. Lett. 7: 87–94, 2014. Medline, Web of Science, Google Scholar
WHO. WHO Handbook for Reporting Results of Cancer Treatment. WHO, Geneva, Switzerland, 1979. Google Scholar
Wu, L., G. Wang, S. Liu, J. Wei, S. Zhang, M. Li, G. Zhou and L. Wang . Synthesis and biological evaluation of matrine derivatives containing benzo-alpha-pyrone structure as potent anti-lung cancer agents. Sci. Rep. 6: 35918, 2016. Crossref, Medline, Web of Science, Google Scholar
Wu, Q.Q., L.S. Liu, Y. Jiang, L.P. Shen and Y.H. Xu . Effect of Chinese medicine treatment based on syndrome differentiation combined with icotinib in treating advanced non-small-cell lung cancer. Chin. J. Integr. Trad. West. Med. 37: 1–5, 2017. Google Scholar
Xu, J.Y., J.X. Li, Z.L. Zhao, H.S. Xue and L.W. Wang . Research on Huaier particles and gefitinib combination treatment in advanced lung adenocarcinoma. Med. Phil. 35: 30–32, 2014. Google Scholar
Yan, X.J., Y. Yang, L. Bi, S.S. Chen, J.J. Zhu and W.P. Chen . Effects of component formula of Salviae Miltiorrhizae Radix et Rhizoma and Ginseng Radix et Rhizoma on cell proliferation, apoptosis and skeleton in lung cancer A549 cells. Chin. J. Chin. Mater. Med. 39: 4436–4441, 2014. Google Scholar
Yang, M.Y., C.H. Hung, C.H. Chang, T.H. Tseng and C.J. Wang . Solanum nigrum suppress angiogenesis-mediated tumor growth through inhibition of the AKT/mTOR pathway. Am. J. Chin. Med. 44: 1273–1288, 2016. Link, Web of Science, Google Scholar
Yang, X.B., X.S. Chai, W.Y. Wu, S.Q. Long, H. Deng, Z.Q. Pan, W.F. He, Y.S. Zhou, G.Y. Liao and S.J. Xiao . Gefitinib plus Fuzheng Kang’ai Formula in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutation: A randomized controlled trial. Chin. J. Integr. Med. 2017. Crossref, Web of Science, Google Scholar
Yates, J.W., B. Chalmer and F.P. McKegney . Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45: 2220–2224, 1980. Crossref, Medline, Web of Science, Google Scholar
Zhang, S.H. and L.X. Zou . Clinical efficacy of gefitinib combined with KLT in treatment of advanced non-small-cell lung cancer. Mod. Oncol. 22: 2857–2859, 2014. Google Scholar
Zhang, X.W., Y. Shao, X.X. Zhang and Y. Zhong . Clinical research on Shenling Baizhu Powder and gefitinib/erlotinib combination treatment in advanced non-small-cell lung cancer patients with syndrome of Spleen Qi deficiency. J. N. Chin. Med. 46: 127–129, 2014. Google Scholar